Autoplaque vs AVIEW
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary focus is highly detailed, quantitative analysis of coronary atherosclerotic plaque and luminal stenoses from CT angiography images. This workstation-based software is ideal for clinicians needing precise measurements of plaque characteristics and stenosis severity to refine heart attack risk prediction and guide targeted treatment strategies, with the ability to review and edit AI-generated segmentations.
View Autoplaque →Choose AVIEW if…
Choose AVIEW if you require a comprehensive AI platform for multi-modal thoracic imaging analysis, including lung cancer screening, COPD assessment, and coronary artery calcium (CAC) scoring from CT scans. This solution is best suited for organizations seeking to streamline radiology workflows with automated detection, characterization, and longitudinal follow-up across multiple conditions, leveraging flexible deployment options and integrated reporting.
View AVIEW →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | AVIEW |
|---|---|---|
| Pricing | Unknown | Subscription; one-off payment |
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEWAVIEW offers flexible deployment options including cloud, hybrid, and local solutions, alongside explicit workflow automation and integration with PACS/RIS/CIS, which streamlines clinical use. Autoplaque is workstation-based, which can be less adaptable in varied clinical environments.
Clinical Value
AVIEWAVIEW provides comprehensive AI-driven solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification, covering multiple critical conditions. Autoplaque specializes in quantitative analysis of coronary plaques and luminal stenoses, offering a more focused, albeit valuable, clinical application.
Pricing & Value
AVIEWAVIEW is transparent about its pricing models, offering both subscription and one-off payment options based on installations or users, which provides clarity for potential buyers. Autoplaque's pricing information is not disclosed, making it difficult to assess its value proposition.
Enterprise Readiness
AVIEWAVIEW explicitly states HIPAA compliance and offers diverse deployment options (cloud, hybrid, local, virtualized) with PACS/RIS/CIS integration, making it highly suitable for enterprise-level adoption. Autoplaque is workstation-based and does not specify HIPAA compliance or BAA availability in the provided information.
Innovation
AVIEWWhile Autoplaque innovates with detailed quantitative coronary plaque and stenosis analysis, AVIEW demonstrates broader innovation by applying AI to a wider range of complex pathologies across multiple organs, including lung nodule characterization, emphysema quantification, ILD pattern analysis, and coronary artery calcium scoring.
Support & Docs
AVIEWCoreline Soft (AVIEW) provides explicit contact information for its customer service team and regional offices, indicating a structured support system. Autoplaque (Cedars-Sinai AIM) has general contact information for its parent entity and implies the existence of user manuals, but lacks specific, dedicated customer support channels.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | AVIEW |
|---|---|---|
| Name | Autoplaque | AVIEW |
| Company | Cedars-Sinai Medical Center: AIM | Coreline Soft Co. |
| Description | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | Coreline Soft's AVIEW AI platform offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, enhancing diagnostic precision and streamlining radiology workflows. |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI, Oncology AI, Radiology & Imaging AI |
| Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
| Key Features | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images; Workstation-based post-processing application; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views; Measurement of vessel diameter and area. | AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score); Emphysema quantification and low attenuation area (LAA) analysis; Coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification); Automated segmentation of lung lobes, airways, vessels, and coronary arteries; 3D visualizations and comprehensive PDF reports; Workflow automation and integration with PACS/RIS/CIS; Follow-up registration and nodule matching for serial CT scans; Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture). |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and AVIEW.